PCM
SYRS

Prelude Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Prelude Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-89,097
Closed -$192K – 1620
2024
Q3 		$192K Buy
89,097
+48,800
+121% +$175K 0.01% 1076
2024
Q2 		$208K Buy
+40,297
New +$212K 0.01% 988
2023
Q2 		– Sell
-14,899
Closed -$39.8K – 1391
2023
Q1 		$39.8K Buy
14,899
+500
+3% +$1.94K ﹤0.01% 1016
2022
Q4 		$51.7K Buy
+14,399
New +$62.5K ﹤0.01% 1129
2021
Q3 		– Sell
-1,420
Closed -$77K – 2088
2021
Q2 		$77K Sell
1,420
-40
-3% -$2.37K ﹤0.01% 1499
2021
Q1 		$109K Buy
1,460
+40
+3% +$4.16K ﹤0.01% 1413
2020
Q4 		$154K Sell
1,420
-30
-2% -$2.74K ﹤0.01% 1150
2020
Q3 		$128K Buy
1,450
+30
+2% +$3.41K 0.01% 825
2020
Q2 		$151K Buy
+1,420
New +$127K 0.01% 821
2019
Q3 		– Sell
-119
Closed -$11K – 2135
2019
Q2 		$11K Buy
+119
New +$8.29K ﹤0.01% 1376
2018
Q3 		– Sell
-75
Closed -$8K – 2097
2018
Q2 		$8K Buy
+75
New +$9.29K ﹤0.01% 1522
2018
Q1 		– Sell
-49
Closed -$5K – 1760
2017
Q4 		$5K Sell
49
-26
-35% -$3.49K ﹤0.01% 1268
2017
Q3 		$11K Sell
75
-46
-38% -$8.65K ﹤0.01% 1424
2017
Q2 		$19K Buy
+121
New +$19K ﹤0.01% 1277

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Prelude Capital Management's SYRS Position: Q4 2024 in Review

Prelude Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 89,097 shares — an estimated $192K sold.

Prelude Capital Management first reported a position in SYRS in Q2 2017 and held it in 14 quarters. The position peaked at $208K in Q2 2024. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Prelude Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 89,097 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $192K.
  • Prelude Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 14 quarters.
  • Prelude Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $208K in Q2 2024.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.